With its 2009 year-end results (and 2010 guidance) due out on Thursday (pre-market) morning, Vertex was just upgraded to "outperform" by Oppenheimer -- per Business Week's online edition:
. . . .An Oppenheimer analyst upgraded the stock of Vertex Pharmaceuticals on the potential of its hepatitis C treatment.
Analyst Dr. Brian Abrahams said Monday that he believes it will be a significant year for the Cambridge, Mass., company, with the experimental drug telaprevir driving its stock.
He upgraded company shares to "outperform" from "perform". . . .
Of course, telaprevir is well-ahead of legacy-Schering-Plough's boceprevir -- in the race for a next-gen Hep C treatment regimen -- on both the timeline-to-approval, and previous Hep C non-responder efficacy measures.
